DNA elements for constitutive androstane receptor- and pregnane X receptor-mediated regulation of bovine CYP3A28 gene.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2019
Historique:
received: 13 01 2019
accepted: 11 03 2019
entrez: 26 3 2019
pubmed: 26 3 2019
medline: 18 12 2019
Statut: epublish

Résumé

The regulation of cytochrome P450 3A (CYP3A) enzymes is established in humans, but molecular mechanisms of its basal and xenobiotic-mediated regulation in cattle are still unknown. Here, ~10 kbp of the bovine CYP3A28 gene promoter were cloned and sequenced, and putative transcription factor binding sites were predicted. The CYP3A28 proximal promoter (PP; -284/+71 bp) contained DNA elements conserved among species. Co-transfection of bovine nuclear receptors (NRs) pregnane X and constitutive androstane receptor (bPXR and bCAR) with various CYP3A28 promoter constructs into hepatoma cell lines identified two main regions, the PP and the distal fragment F3 (-6899/-4937 bp), that were responsive to bPXR (both) and bCAR (F3 fragment only). Site-directed mutagenesis and deletion of NR motif ER6, hepatocyte nuclear factor 1 (HNF-1) and HNF-4 binding sites in the PP suggested either the involvement of ER6 element in bPXR-mediated activation or the cooperation between bPXR and liver-enriched transcription factors (LETFs) in PP transactivation. A putative DR5 element within the F3 fragment was involved in bCAR-mediated PP+F3 transactivation. Although DNA enrichment by anti-human NR antibodies was quite low, ChIP investigations in control and RU486-treated BFH12 cells, suggested that retinoid X receptor α (RXRα) bound to ER6 and DR5 motifs and its recruitment was enhanced by RU486 treatment. The DR5 element seemed to be recognized mainly by bCAR, while no clear-cut results were obtained for bPXR. Present results point to species-differences in CYP3A regulation and the complexity of bovine CYP3A28 regulatory elements, but further confirmatory studies are needed.

Identifiants

pubmed: 30908543
doi: 10.1371/journal.pone.0214338
pii: PONE-D-19-00855
pmc: PMC6433341
doi:

Substances chimiques

Constitutive Androstane Receptor 0
Pregnane X Receptor 0
Receptors, Cytoplasmic and Nuclear 0
Transcription Factors 0
Cytochrome P-450 CYP3A EC 1.14.14.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0214338

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Adv Drug Deliv Rev. 2002 Nov 18;54(10):1271-94
pubmed: 12406645
Xenobiotica. 2015 May;45(5):373-9
pubmed: 25413352
Bioinformatics. 2005 Jul 1;21(13):2933-42
pubmed: 15860560
Mol Endocrinol. 2005 Mar;19(3):595-606
pubmed: 15563547
Drug Metab Dispos. 2015 Sep;43(9):1336-40
pubmed: 26070839
Mol Pharmacol. 2002 Aug;62(2):359-65
pubmed: 12130689
Curr Drug Metab. 2011 Jul;12(6):507-25
pubmed: 21476973
Mol Pharm. 2011 Dec 5;8(6):2424-33
pubmed: 22044162
Exp Biol Med (Maywood). 2010 Jun;235(6):718-36
pubmed: 20511676
Mol Pharmacol. 1999 Dec;56(6):1329-39
pubmed: 10570062
Biochem J. 2008 Jan 1;409(1):243-50
pubmed: 17764444
PLoS One. 2018 Mar 15;13(3):e0194420
pubmed: 29543899
Biochem Pharmacol. 2009 Feb 1;77(3):451-63
pubmed: 19022227
Xenobiotica. 2015;45(7):563-70
pubmed: 25630049
J Biol Chem. 2004 Aug 6;279(32):33558-66
pubmed: 15151997
Comp Biochem Physiol C Toxicol Pharmacol. 2018 Dec;214:9-16
pubmed: 30153482
Pharmacogenet Genomics. 2010 Mar;20(3):167-78
pubmed: 20147837
J Clin Invest. 1998 Sep 1;102(5):1016-23
pubmed: 9727070
Genes Dev. 1998 Oct 15;12(20):3195-205
pubmed: 9784494
Pharmacol Ther. 2013 Apr;138(1):103-41
pubmed: 23333322
Nucleic Acids Res. 1994 Apr 11;22(7):1242-6
pubmed: 8165139
Biochem Pharmacol. 2011 Dec 15;82(12):1994-2007
pubmed: 21924250
Mol Endocrinol. 2002 Jun;16(6):1269-79
pubmed: 12040014
Drug Metab Dispos. 2008 May;36(5):885-93
pubmed: 18268077
Trends Endocrinol Metab. 2000 Sep;11(7):281-5
pubmed: 10920385
Curr Drug Metab. 2017;18(12):1095-1105
pubmed: 28558634
Vet Res Commun. 2001 Jul;25(5):345-54
pubmed: 11469506
Xenobiotica. 2009 Dec;39(12):915-30
pubmed: 19925382
Mol Pharmacol. 2004 Feb;65(2):326-34
pubmed: 14742674
J Vet Pharmacol Ther. 2001 Dec;24(6):399-403
pubmed: 11903870
J Anim Physiol Anim Nutr (Berl). 2007 Feb;91(1-2):62-7
pubmed: 17217392
J Vet Pharmacol Ther. 2010 Dec;33(6):528-36
pubmed: 21062304
PLoS One. 2008;3(11):e3669
pubmed: 18989361
Vet J. 2014 Oct;202(1):106-11
pubmed: 25193407
Domest Anim Endocrinol. 2006 Jul;31(1):76-87
pubmed: 16236479
Nucleic Acids Res. 1995 Feb 11;23(3):395-404
pubmed: 7533900
Drug Metab Dispos. 2015 Oct;43(10):1458-67
pubmed: 26182937
Drug Metabol Drug Interact. 2013;28(2):79-93
pubmed: 23729557
Vet Res. 2005 Mar-Apr;36(2):179-90
pubmed: 15720971
PLoS One. 2018 May 8;13(5):e0197126
pubmed: 29738563
Eur J Pharm Sci. 2010 Jul 11;40(4):263-72
pubmed: 20381613
Xenobiotica. 2012 Nov;42(11):1096-109
pubmed: 22694178
Biochem Biophys Res Commun. 2014 Mar 7;445(2):469-74
pubmed: 24525126
Biochem Biophys Res Commun. 2000 Aug 11;274(3):746-9
pubmed: 10924348
In Vitro Cell Dev Biol Anim. 2016 Jun;52(6):662-72
pubmed: 27071625
Mol Aspects Med. 2009 Oct;30(5):297-343
pubmed: 19427329
J Biol Chem. 1999 Mar 5;274(10):6043-6
pubmed: 10037683
Drug Metab Pharmacokinet. 2015 Apr;30(2):188-97
pubmed: 25989892
Toxicol In Vitro. 2000 Aug;14(4):321-7
pubmed: 10906438
J Biol Chem. 2003 Oct 31;278(44):43299-310
pubmed: 12896978
Mol Pharmacol. 1996 Jul;50(1):10-6
pubmed: 8700101
Methods Mol Biol. 2010;634:157-74
pubmed: 20676983
Drug Metab Rev. 2006;38(3):515-97
pubmed: 16877263
Pharm Res. 2001 Feb;18(2):146-50
pubmed: 11405283
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
J Biol Chem. 1997 Oct 31;272(44):27493-6
pubmed: 9346875
Xenobiotica. 2016;46(3):200-10
pubmed: 26153444
Res Vet Sci. 1999 Feb;66(1):51-5
pubmed: 10088712
PLoS One. 2012;7(1):e30895
pubmed: 22292071
PLoS One. 2016 Mar 21;11(3):e0152114
pubmed: 26999742
Mol Pharmacol. 2007 Sep;72(3):514-25
pubmed: 17548528
Proc Natl Acad Sci U S A. 1998 Oct 13;95(21):12208-13
pubmed: 9770465
Front Genet. 2013 Feb 25;4:12
pubmed: 23444277
Res Vet Sci. 2011 Apr;90(2):235-7
pubmed: 20557914
Mol Pharmacol. 2002 Aug;62(2):366-78
pubmed: 12130690

Auteurs

Mery Giantin (M)

Department of Comparative Biomedicine and Food Science, University of Padua, Legnaro, Padua, Italy.

Jenni Küblbeck (J)

Faculty of Health Sciences, School of Pharmacy, University of Eastern Finland, Kuopio, Finland.

Vanessa Zancanella (V)

Department of Comparative Biomedicine and Food Science, University of Padua, Legnaro, Padua, Italy.

Viktoria Prantner (V)

Faculty of Health Sciences, School of Pharmacy, University of Eastern Finland, Kuopio, Finland.

Fabiana Sansonetti (F)

Department of Comparative Biomedicine and Food Science, University of Padua, Legnaro, Padua, Italy.

Axel Schoeniger (A)

Institute of Biochemistry, University of Leipzig, Leipzig, Germany.

Roberta Tolosi (R)

Department of Comparative Biomedicine and Food Science, University of Padua, Legnaro, Padua, Italy.

Giorgia Guerra (G)

Department of Comparative Biomedicine and Food Science, University of Padua, Legnaro, Padua, Italy.

Silvia Da Ros (S)

Department of Comparative Biomedicine and Food Science, University of Padua, Legnaro, Padua, Italy.

Mauro Dacasto (M)

Department of Comparative Biomedicine and Food Science, University of Padua, Legnaro, Padua, Italy.

Paavo Honkakoski (P)

Faculty of Health Sciences, School of Pharmacy, University of Eastern Finland, Kuopio, Finland.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH